DEF: Bausch Health Seeks Shareholder Approval for Rights Plan

Bausch Health Companies Inc. calls a Special Meeting for October 7, 2025, to ratify its recently adopted shareholder rights plan, aimed at ensuring fair treatment for all shareholders in potential take-over bids.

Summary

• A Special Meeting of shareholders will be held via live webcast on October 7, 2025, at 9:00 A.M., Eastern Time.
• The primary business of the Special Meeting is to approve an ordinary resolution ratifying, confirming, and approving the adoption of the Company's Amended and Restated Shareholder Rights Plan (the Rights Plan).
• The Rights Plan was initially adopted on April 14, 2025, and is intended to ensure all shareholders are treated equally and fairly in connection with any unsolicited take-over bid or other acquisition of control.
• The plan encourages potential acquirors to make take-over bids by means of a 'Permitted Bid' or to approach the Board to negotiate a mutually acceptable transaction.
• The Rights Plan is similar to those adopted by other Canadian public companies and is considered consistent with current Canadian corporate governance best practices.
• The Board of Directors unanimously recommends and urges shareholders to vote FOR the proposal.
• The Rights Agreement will be amended and restated following the Special Meeting to remove provisions related to a Director Appointment and Nomination Agreement (DANA) that terminated on August 15, 2025.
• The Rights Plan must be reconfirmed at every third annual meeting of shareholders thereafter to continue to have effect.
• The record date for shareholders entitled to vote at the Special Meeting was August 18, 2025, with 369,800,365 Common Shares outstanding.
• Key beneficial owners as of August 18, 2025, include Paulson & Co. Inc. (19.13%), Mr. Alex Meruelo (9.90%), GoldenTree Asset Management, L.P. (9.53%), and Nomura Holdings, Inc. (5.81%).

Sentiment

Score: 7

Explanation: The filing outlines a proactive measure to protect shareholder interests and ensure fair treatment in potential takeovers, aligning with good governance practices. While such plans can sometimes be viewed negatively, the company emphasizes its defensive, not preventative, nature and adherence to Canadian best practices.

Positives

• The Rights Plan aims to ensure all shareholders are treated equally and fairly in connection with any unsolicited take-over bid or acquisition of control.
• It encourages potential acquirors to make 'Permitted Bids' or negotiate with the Board, potentially leading to better outcomes for all shareholders.
• The plan is designed to prevent 'creeping take-overs,' where control is acquired gradually without paying full value or sharing a control premium equally among all shareholders.
• The Board believes the Rights Plan is consistent with current Canadian corporate governance best practices and institutional investor guidelines.
• The adoption of the plan is a proactive measure, as the Board is not aware of any pending or threatened take-over bid for the Company.

Negatives

• The Rights Plan could be perceived by some as a mechanism for board entrenchment, despite the company's statement that it does not prevent take-overs.
• The plan creates the potential for significant dilution to the holdings of an 'Acquiring Person' if shares are not acquired in a manner permitted by the Rights Plan, which could complicate future M&A activity.
• The requirement for reconfirmation at every third annual meeting adds a recurring governance item that requires shareholder attention and voting.

Risks

• Creeping Take-overs: The risk of an unsolicited or hostile acquiror obtaining control or effective control through a number of purchases exempt from Canadian take-over bid rules over time, including private acquisitions.
• Auction-preventing Lock-up Agreements: The risk of unsolicited or hostile acquirors entering into 'hard lock-up agreements' where existing shareholders commit to tender their shares, potentially limiting competitive bids.
• Dilution: The potential for significant dilution to the holdings of an 'Acquiring Person' if a 'Flip-in Event' occurs and they are not entitled to exercise Rights, which could deter certain types of acquisition attempts.

Future Outlook

The Shareholder Rights Plan, if ratified, will require reconfirmation by shareholders at every third annual meeting thereafter to remain effective. The Board is not aware of any pending or threatened take-over bid for the Company, indicating the plan is a proactive governance measure.

Management Comments

• "On behalf of the Board of Directors of Bausch Health Companies Inc. (the Company), you are cordially invited to attend the Special Meeting of shareholders of the Company..."
• "The Rights Plan is intended to ensure that all our shareholders are treated equally and fairly in connection with any unsolicited take-over bid or other acquisition of control of the Company."
• "To be clear, the Rights Plan does not prevent take-overs; rather it encourages potential acquirors of control to make take-over bids by means of a permitted bid under the Rights Plan, which shareholders may tender to regardless of the acceptability of the bid to the Board or to approach the Board to negotiate a mutually acceptable transaction."
• "The Company's Board of Directors has determined that the proposal, ratifying, confirming and approving the shareholder rights plan, to be presented to the shareholders at the Special Meeting is in the best interests of the Company and its stockholders and recommends and urges you to vote FOR the proposal set forth in this Proxy Statement."
• "The Board believes that the Rights Plan is consistent with current Canadian corporate governance best practices and institutional investor guidelines."
• "The Rights Plan is not being adopted in response to any specific proposal to acquire control of the Company, and the Board is not aware of any pending or threatened take-over bid for the Company."

Industry Context

Shareholder rights plans, often referred to as 'poison pills,' are a common corporate governance tool, particularly among Canadian public companies, to deter hostile takeovers and ensure that the board has sufficient time and leverage to negotiate the best possible outcome for all shareholders in the event of an unsolicited bid. The filing explicitly states that Bausch Health's plan is 'similar to the shareholder rights plans adopted by other Canadian public companies' and 'consistent with current Canadian corporate governance best practices and institutional investor guidelines,' indicating its alignment with established industry defensive strategies.

Comparison to Industry Standards

• The Rights Plan is explicitly stated to be 'similar to the shareholder rights plans adopted by other Canadian public companies,' suggesting adherence to common defensive strategies in the Canadian market.
• The plan is also deemed 'consistent with current Canadian corporate governance best practices and institutional investor guidelines,' indicating it meets recognized standards for shareholder protection and board oversight.
• Key features, such as the 20% beneficial ownership threshold for an 'Acquiring Person' and the 105-day minimum open period for a 'Permitted Bid,' align with typical provisions found in Canadian rights plans, often influenced by National Instrument 62-104 Take-Over Bids and Issuer Bids.

Corporate Governance

Stakeholder Impact

• Shareholders: The Rights Plan is intended to ensure fair and equal treatment for all shareholders in the event of an unsolicited take-over bid, protecting against control being acquired without full value or an equitable sharing of any control premium. It provides the Board with more time and leverage to negotiate for better terms for all shareholders.

Next Steps

• Shareholders are to vote on the ratification of the Amended and Restated Shareholder Rights Plan at the Special Meeting on October 7, 2025.
• The Rights Agreement will be amended and restated following the Special Meeting to remove provisions related to the terminated Director Appointment and Nomination Agreement (DANA).
• If ratified, the Rights Plan will require reconfirmation at every third annual meeting of shareholders thereafter.

Key Dates

Recommendation

This filing concerns the ratification of a shareholder rights plan, a standard corporate governance measure designed to protect against hostile takeovers and ensure fair treatment of all shareholders. It is not a financial performance report or a strategic announcement that would fundamentally alter the company's valuation or operational outlook. The plan is described as consistent with Canadian best practices and not in response to any specific threat. Therefore, it does not provide a basis for a change in investment recommendation; a 'hold' stance is appropriate as it maintains the status quo regarding the company's defensive posture.

Keywords

Bausch Health, Shareholder Rights Plan, Corporate Governance, Takeover Defense, Proxy Statement, Special Meeting, Shareholder Vote, Canada, Pharmaceutical, Healthcare, DEF 14A